GB0301016D0 - Treatment of benign prostatic hyperplasia - Google Patents

Treatment of benign prostatic hyperplasia

Info

Publication number
GB0301016D0
GB0301016D0 GBGB0301016.2A GB0301016A GB0301016D0 GB 0301016 D0 GB0301016 D0 GB 0301016D0 GB 0301016 A GB0301016 A GB 0301016A GB 0301016 D0 GB0301016 D0 GB 0301016D0
Authority
GB
United Kingdom
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
hyperplasia
benign
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0301016.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to GBGB0301016.2A priority Critical patent/GB0301016D0/en
Publication of GB0301016D0 publication Critical patent/GB0301016D0/en
Priority to PCT/GB2004/000139 priority patent/WO2004062666A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
GBGB0301016.2A 2003-01-16 2003-01-16 Treatment of benign prostatic hyperplasia Ceased GB0301016D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0301016.2A GB0301016D0 (en) 2003-01-16 2003-01-16 Treatment of benign prostatic hyperplasia
PCT/GB2004/000139 WO2004062666A2 (en) 2003-01-16 2004-01-16 Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0301016.2A GB0301016D0 (en) 2003-01-16 2003-01-16 Treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
GB0301016D0 true GB0301016D0 (en) 2003-02-19

Family

ID=9951274

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0301016.2A Ceased GB0301016D0 (en) 2003-01-16 2003-01-16 Treatment of benign prostatic hyperplasia

Country Status (2)

Country Link
GB (1) GB0301016D0 (en)
WO (1) WO2004062666A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4895806B2 (en) * 2003-04-09 2012-03-14 エクセリクシス， インク． TIE-2 modulator and usage
CR9465A (en) * 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
CN105367555B (en) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
WO2017150174A1 (en) * 2016-03-04 2017-09-08 株式会社シンスター・ジャパン Pharmaceutical composition containing 2,4-diaminoquinazoline derivative or salt thereof as active ingredient, and 2,4-diaminoquinazoline derivative having specific structure
US11376252B2 (en) * 2017-12-30 2022-07-05 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in prostatic hyperplasia and urinary track diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
EP1174150A4 (en) * 1999-04-22 2004-06-16 Mitsubishi Pharma Corp Preventives/remedies for angiostenosis
US6399115B2 (en) * 1999-09-10 2002-06-04 Glenn Braswell Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
DE10226943A1 (en) * 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidines and their use

Also Published As

Publication number Publication date
WO2004062666A3 (en) 2004-10-07
WO2004062666A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
EP1887976B8 (en) Devices for treating benign prostatic hyperplasia and other conditions
EP1390014A4 (en) Composition and methods for treatment of hyperplasia
EP1667680A4 (en) Combination methods of treating cancer
IL186604A0 (en) Therapeutic combination in case of benign prostate hyperplasia
EP1385434A4 (en) Treatment of vault prolapse
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1368024A4 (en) Treatment of restenosis
EP1320376A4 (en) Treatment of prostate cancer
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
MXPA03008582A (en) Agents and methods for treatment of cancer.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
EP2083840A4 (en) Improved treatment for benign prostatic hyperplasia
HK1085373A1 (en) Compound and use in the manufacture of a medicament for the treatment of benign prostatic hyperplasia and associated symptoms
IL145397A0 (en) Compositions and methods for treatment of cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB0301016D0 (en) Treatment of benign prostatic hyperplasia
GB0124124D0 (en) Methods of treatment
GB0324523D0 (en) Compositions and methods of treatment
EP1485117A4 (en) Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
EP1372639A4 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
GB0317500D0 (en) Treatment of bph
IL178303A0 (en) Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia
EP1684795A4 (en) Methods and agents for the treatment of cancer
GB0329416D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)